ICBII UPDATE: THE ROAD TO THE CURE A REAL-TIME SCIENCE REPORTCategory:
ICBII UPDATE: THE ROAD TO THE CURE
A REAL-TIME SCIENCE REPORT
Optimization of our Parkinson’s Drug during the CoVid-19 Pandemic
Ram Bhatt, Ph.D., CEO, ICBII
Optimization of our Parkinson’s Drug – The scientists at ICB International, Inc. have been busy since New Year optimizing their Parkinson’s drug to accomplish two major goals:
To introduce the best possible drug into the market with unquestionable safety and therapeutic efficacy.
To monitor the effect of therapy in the shortest possible time.
The present drug will take nearly a day to radiolabel it, inject it in the patient and scan the brain to monitor what the drug is doing in the brain. Some physicians have advised us to shorten the monitoring time to about 2-3 hours. To achieve this goal, we have designed eight analogs of the current Parkinson’s drug. Gen-Script, a company in New Jersey, has been helping ICBII scientists to generate eight different DNA vectors. As soon as these vectors are ready, ICBII will express them to generate eight new SMART Molecules, which will then be tested in animal models both in house and at Charles River’s Laboratory, Finland. This is a very comprehensive program that will require nearly 9 to 12 months to complete with a budget of about $2M.
The Coronavirus Havoc – The Coronavirus has created havoc worldwide both in human and economic costs. The cost of loss of human life is immeasurable. A vaccine is estimated to be at least 18 months away. Experiments with unconventional therapies such as the combination therapy with hydroxy-chloro-quinine, Azithromycin, and viral drugs have begun, including the use of serum from patients recovered from the CoV infection and mouse monoclonal antibodies. It is conceivable that these therapies could have a phenomenal impact that can combat the growing threat of CoV and end the loss of life all over the world. But if the benefit of these drugs is marginal. Under that scenario, developing alternative therapies will be a wise move. While practicing CDC outlined preventive tips will help mitigate the virus spread but it will not be a substitute for the curative treatment.
The ICBII scientists are facing a big dilemma. Scientists are confident that our SMART Molecules based therapy can be ready long before a vaccine will be ready. However, if ICBII starts developing today, a coronavirus therapy would not be ready for at least 12 months. The dilemma is that the threat of coronavirus may be minimized or eradicated in the next few months due to parameters such as hot weather, pursuit of safety and prevention tips, and use of new drugs and antibodies, etc. If such a wonderful turn of events takes place, there would not be a need for these new therapies and ICBII would just be wasting resources. However, if our wishful thinking does not materialize, ICBII would regret not coming to rescue society from the coronavirus plague.
Developing new drugs is not an inexpensive process either. I am sure you have heard figures upwards of $2 Billion in the news for a CoV vaccine. Due to the unique characteristics of ICBII’s SMART Molecules, scientists believe that they could demonstrate proof of principle and conduct Phase-1 clinical trials with a budget of $15M, much less than what is being projected by the elite groups; Notwithstanding, ICBII will stay developing its Parkinson’s drugs for the time being.